Emergent BioSolutions (EBS) Set to Announce Earnings on Wednesday

Emergent BioSolutions (NYSE:EBS) is scheduled to release its earnings data after the market closes on Wednesday, May 1st. Analysts expect Emergent BioSolutions to post earnings of ($3.65) per share for the quarter. Emergent BioSolutions has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

Emergent BioSolutions (NYSE:EBS) last released its earnings results on Wednesday, March 6th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.44). The business had revenue of $276.60 million during the quarter, compared to the consensus estimate of $247.63 million. Emergent BioSolutions had a negative net margin of 72.11% and a negative return on equity of 37.35%. During the same period in the prior year, the company earned ($0.31) earnings per share. On average, analysts expect Emergent BioSolutions to post $-14 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Emergent BioSolutions Price Performance

Shares of Emergent BioSolutions stock opened at $2.29 on Wednesday. The business’s fifty day simple moving average is $2.43 and its 200 day simple moving average is $2.25. The company has a current ratio of 1.04, a quick ratio of 0.54 and a debt-to-equity ratio of 0.69. Emergent BioSolutions has a 12 month low of $1.42 and a 12 month high of $10.88.

Analyst Upgrades and Downgrades

Separately, Benchmark reiterated a “buy” rating and set a $5.00 target price on shares of Emergent BioSolutions in a research note on Thursday, April 11th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.